Drugs / DE-117B
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06666855 | Nov 2024 → Aug 2026 overdue | ocular hypertension, open-angle glaucoma | Santen Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DE-117B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06666855 ↗ |
| Route | Topical | “0.002% DE-117B Eye Drops - One drop daily, 9:00 PM±1 hours instilled in both eyes” NCT06666855 ↗ |